Dato-DXd
Breast Cancer
Optimal dosage justification for datopotamab deruxtecan in HR-positive/HER2-negative breast cancer through model-informed drug development approaches
Tang Z, Lim K, Jiang Y, et al.
Clin Transl Sci. 2026 Feb;19(2):e70493. doi: 10.1111/cts.70493.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: A plain language summary of the DESTINY-Lung02 study
Jänne PA.
Future Oncol. 2026 Mar;22(6):659-670. doi: 10.1080/14796694.2025.2598216.
T-DXd
Breast Cancer
Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: A systematic review and indirect treatment comparison
Cappuzzo F, Zhang L, Dunton K, Dennis N, Le Nouveau P, Nevière A, Gauthier A.
Front Oncol. 2026 Feb 13;15:1708245. doi: 10.3389/fonc.2025.1708245.
Dato-DXd
Lung Cancer
TROPION-Lung10: A phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
Newsom-Davis T, Melosky B, Heist RS, et al.
Front Oncol. 2026 Feb 11;16:1804953. doi: 10.3389/fonc.2026.1804953.
Quizartinib
Hematology
FLT3-ITD measurable residual disease from the QuANTUM-First trial
Levis MJ, Erba HP, Montesinos P, et al.
Blood Adv. 2026 Feb 10;10(3):917-928. doi: 10.1182/bloodadvances.2025016444.
Edoxaban
Cardiovascular - AF
Major bleeding risk assessment with atrial fibrillation post-TAVR: The HARHP score results from ENVISAGE-TAVI AF
Dangas GD, Unverdorben M, Hengstenberg C, et al.
JACC Cardiovasc Interv. 2026 Feb 9;19(3):359-368. doi: 10.1016/j.jcin.2025.11.028.
T-DXd
Breast Cancer
Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Modi S, Byng D, Zhang S, et al.
Breast. 2026 Apr;86:104721. doi: 10.1016/j.breast.2026.104721.
T-DXd
Breast Cancer
Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease
Tsurutani J, Nozawa K, Mukohara T, et al.
Breast. 2026 Apr;86:104722. doi: 10.1016/j.breast.2026.104722.
T-DXd
Breast Cancer
Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan
Tsurutani J, Noguchi K, Tanabe A.
Breast Cancer. 2026 Mar;33(2):346-358. doi: 10.1007/s12282-025-01814-3.
Edoxaban
Cardiovascular - AF
Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study
Guo X, Du J, Yin Y, et al.
Front Pharmacol. 2026 Jan 22;17:1739246. doi: 10.3389/fphar.2026.1739246.